Hims & Hers and other telehealth platforms offer the Galleri test to detect the signal of more than 50 types of blood cancers before symptoms appear[2][3][6][7]. The test was developed by Grail and serves as an adjunct to standard screening, particularly for adults over 50 at higher risk[1][2][3]. The Pathfinder 2 study of nearly 36,000 adults over 50 showed a test sensitivity of 40.4%, with more than half of the cancers detected being stage 1 or 2[1]. Three-quarters of detected cancers included types without standard screening, such as pancreatic, liver, and head and neck cancers[1]. Among patients with a positive result, 62% actually had cancer, while 38% were false positives; the negative predictive value reached 99.1%[1]. The test is not FDA approved, requires a prescription, and can lead to false positive or negative results[2][3][6]. Doctors warn against misleading patients with false negatives or unnecessary care[6].